Q-omics provides the consensus-scored RAB3B profile across patient tissues and cancer cell-line models. RAB3B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB3B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAB3B protein abundance shows 20,502 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where RAB3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB3B survival associations across molecular data types. RAB3B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB3B RNA expression–survival associations across cancer types. High RAB3B expression shows unfavorable associations in KIRC, MESO, STAD, UVM, CESC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB3B RNA expression.
This table summarizes RAB3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB3B shows lower tumor expression in KIRC and COAD and higher tumor expression in HNSC, LUAD, LIHC and THCA. The HNSC box plot shows higher RAB3B RNA expression in tumor versus normal tissue (log2 FC = +2.118, t-test p < 0.001).
This table shows molecular features associated with RAB3B in patient tissues and cancer cell lines. In patient samples, RAB3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
